Discussion {#onco12156-sec-0001}
==========

High Ang‐2 levels' association with poor outcome in HCC for patients treated with sorafenib or placebo has been reported \[[1](#onco12156-bib-0001){ref-type="ref"}\]. Adding trebananib, which sequesters Ang‐1 and Ang‐2, preventing their interaction with the Tie‐2 receptor \[[2](#onco12156-bib-0002){ref-type="ref"}\], to sorafenib treatment on a continuous schedule in two nonrandomized cohorts of two doses of trebananib with comparable demographics between the two arms and the historical control did not show an improvement in progression‐free survival (PFS) rate at 4 months, compared with the estimate of historical control sorafenib in patients with advanced HCC. This is, albeit a favorable median PFS of 7.9 for the 10 mg/kg arm, a reminder of the difficulty of interpreting these endpoints vis‐à‐vis the complexity of HCC and the accompanying cirrhosis.

The combination of trebananib plus sorafenib seems relatively well tolerated; however, the relatively higher than anticipated worsening of liver function is a concern and may add some pretext to the relatively poor outcome of the higher dose of 15 mg/kg cohort compared with the lower dose of 10 mg/kg cohort.

The exploratory biomarker analyses showed several patterns, among which the most intriguing finding is the lower baseline Ang‐2 at study entry, suggesting an association with improved OS to 22 months (Fig. [1](#onco12156-fig-0001){ref-type="fig"}). The association between Ang‐2 and survival was previously observed (*p* \< .006) in a phase II trial of trebananib plus sunitinib in renal cancer patients \[[3](#onco12156-bib-0003){ref-type="ref"}\].

![Kaplan‐Meier curves depicting overall survival in the Ang‐2 \>5,700 ng/mL and \<5,700 ng/mL dichotomized 10 mg/kg trebananib arm.\
Abbreviations: HR, hazard ratio; NE, not evaluable.](onco12156-fig-0001){#onco12156-fig-0001}

A relatively improved estimate of 17 months median OS of the 10 mg/kg compared with 11 months of the 15 mg/kg trebananib cohort, which is commensurate with the sorafenib single agent historical control of 10.7 months \[[4](#onco12156-bib-0004){ref-type="ref"}\], is noted. We do not believe that the biology of trebananib could explain a lower dose improved efficacy or synergy with sorafenib. This may likely be an artifact of the Kaplan‐Meier curve estimation and censoring.

In conclusion, the combination of sorafenib and trebananib did not demonstrate improved control of tumor growth at 4 months, the primary endpoint of this trial. Any further studies of this combination or similar in HCC should be studied within the context of low baseline Ang‐2 and possibly other markers reported herein.

Trial Information {#onco12156-sec-1101}
=================

**Disease**Hepatocellular carcinoma**Stage of Disease/Treatment**Metastatic/Advanced**Prior Therapy**None**Type of Study ‐ 1**Phase II**Type of Study ‐ 2**Randomized**ORR**RECIST 1.0 objective response rates were 3% and 7%, for the 10 mg/kg and 15 mg/kg cohorts, respectively.**PFS**PFS rates at 4 months were 57% and 54% for the 10 mg/kg and 15 mg/kg trebananib cohorts, respectively.**TTP**Median TTP was 9 months (95% CI: 3.4, 16.4) and 6.9 months (95% CI: 3.6, 12.7) in the 10 mg/kg and 15 mg/kg trebananib cohorts, respectively.**Response Duration**There was no significant difference in the rate of durable stable disease at ≥16 weeks from study day 1 (46.7% and 40% on the 10 mg/kg and 15 mg/kg trebananib cohorts, respectively). This translated into a disease controlled rate of 50% and 46.7% in the 10 mg/kg arm and 15 mg/kg arm, respectively.**Primary Endpoint**Progression‐free survival at 4 months**Secondary Endpoint**Toxicity**Secondary Endpoint**Overall survival**Secondary Endpoint**Progression‐free survival**Secondary Endpoint**Time to progression**Secondary Endpoint**Overall response rate**Secondary Endpoint**Pharmacokinetics**Secondary Endpoint**Correlative endpoint**Additional Details of Endpoints or Study Design** The study consisted of two sequentially enrolled cohorts of trebananib 10mg/kg and trebananib 15mg/kg, each dosed weekly in combination with sorafenib given at the standard dose of 400mg twice daily in an every‐4‐weeks dosing schedule. Based on an estimated 4‐month progression‐free survival rate of 62% for sorafenib single agent \[5\], and assuming a 4‐month progression‐free survival rate of 78% in each cohort, 30 patients in each cohort were required to accrue to satisfy a power of 80% with the one‐sided exact test for single proportion at α = 0.20. Survival curves were estimated using the Kaplan‐Meier methodology. The safety, tolerability, and adverse events were summarized using descriptive statistics. Patients who received at least one dose of trebananib plus sorafenib were evaluable for toxicity. 

Drug Information for Phase II Trebananib 10mg/kg + sorafenib {#onco12156-sec-1201}
============================================================

Drug 1 Generic/Working nameTrebananibCompany nameAmgenDrug typePeptibodyDose10 milligrams (mg) per kilogram (kg)RouteIntravenous (IV)Schedule of AdministrationOnce a weekDrug 2 Generic/Working nameSorafenibTrade nameNexavarCompany nameBayerDrug typeSmall moleculeDose400 milligrams (mg) per flat doseRouteOral (PO)

Drug Information for Phase II Trebananib 15mg/kg + sorafenib {#onco12156-sec-1301}
============================================================

Drug 1 Generic/Working nameTrebananibCompany nameAmgenDrug typePeptibodyDose15 milligrams (mg) per kilogram (kg)RouteIntravenous (IV)Schedule of AdministrationOnce a weekDrug 2 Generic/Working nameSorafenibTrade nameNexavarCompany nameBayerDrug typeSmall moleculeDrug class Dose400 milligrams (mg) per flat doseRouteOral (PO)

Patient Characteristics for Phase II Trebananib 10mg/kg + sorafenib {#onco12156-sec-1401}
===================================================================

**Number of patients, male**50**Number of patients, female**10**Stage**Macroscopic Vascular Invasion: trebananib 10mg/kg + sorafenib, *n* = 30: 8 (26.7) Macroscopic Vascular Invasion: trebananib 15mg/kg + sorafenib, *n* = 30: 8 (26.7) Extrahepatic Spread: trebananib 10mg/kg + sorafenib, *n* = 30: 10 (33.3) Extrahepatic Spread: trebananib 15mg/kg + sorafenib, *n* = 30: 10 (33.3)**Age**Median (range): 64 and 60 per arm**Number of prior systemic therapies**Median (range): 0**Performance Status: ECOG**0 --- 1 --- 57 (0--1) 2 --- 3 --- unknown --- 3

 {#onco12156-sec-1501}
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Patient Characteristics for Phase II Trebananib 15mg/kg + sorafenib {#onco12156-sec-1601}
===================================================================

**Number of patients, male**50**Number of patients, female**10**Stage**Macroscopic Vascular Invasion: trebananib 10mg/kg + sorafenib, *n* = 30: 8 (26.7) Macroscopic Vascular Invasion: trebananib 15mg/kg + sorafenib, *n* = 30: 8 (26.7) Extrahepatic Spread: trebananib 10mg/kg + sorafenib, *n* = 30: 10 (33.3) Extrahepatic Spread: trebananib 15mg/kg + sorafenib, *n* = 30: 10 (33.3)**Age**Median (range): 64 and 60 per arm**Number of prior systemic therapies**Median (range): 0**Performance Status: ECOG**0 --- 1 --- 57 (0--1) 2 --- 3 --- unknown --- 3

 {#onco12156-sec-1701}
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Primary Assessment Method for Phase II Trebananib 10mg/kg + sorafenib {#onco12156-sec-1801}
=====================================================================

Assessment Number of patients enrolled30Number of patients evaluable for toxicity30Number of patients evaluated for efficacy30Response assessment CR*n =* 0 (0%)Response assessment PR*n =* 1 (3%)Response assessment SD*n =* 14 (47%)Response assessment PD*n =* 15 (50%)Response assessment OTHER*n =* 0 (0%)(Median) duration assessments PFS7.9 months, 95% CI: 3.1--12.6(Median) duration assessments TTP9 months, 95% CI: 3.4--16.4(Median) duration assessments OS17 months, 95% CI: 8.6--27.4(Median) duration assessments duration of treatment5.5 months

Primary Assessment Method for Phase II Trebananib 15mg/kg + sorafenib {#onco12156-sec-1956}
=====================================================================

Assessment Number of patients enrolled30Number of patients evaluable for toxicity30Number of patients evaluated for efficacy30Response assessment CR*n =* 0 (0%)Response assessment PR*n =* 2 (7%)Response assessment SD*n =* 12 (40%)Response assessment PD*n =* 16 (53%)Response assessment OTHER*n =* 0 (0%)(Median) duration assessments PFS5.5 months, 95% CI: 3.9--9(Median) duration assessments TTP6.9 months, 95% CI: 3.6--12.7(Median) duration assessments OSThe median overall survival was 17 months (95% CI: 8.6, 27.4) and 11 months (95% CI: 6.7, not evaluable).(Median) duration assessments duration of treatment3.5 monthsAssessment Number of patients enrolled30Number of patients evaluable for toxicity30Number of patients evaluated for efficacy30Response assessment CR*n =* 0 (0%)Response assessment PR*n =* 2 (7%)Response assessment SD*n =* 12 (40%)Response assessment PD*n =* 16 (53%)Response assessment OTHER*n =* 0 (0%)(Median) duration assessments PFS5.5 months, 95% CI: 3.9--9(Median) duration assessments TTP6.9 months, 95% CI: 3.6--12.7(Median) duration assessments OS11 months, 95% CI: 6.7, not evaluable(Median) duration assessments duration of treatment3.5 months

Adverse events: Phase II trebananib 10mg/kg + sorafenib {#onco12156-sec-2181}
=======================================================
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Pharmacokinetics/Pharmacodynamics {#onco12156-sec-2201}
=================================

Cmax and Cmin of the trebananib and sorafenib at the end of infusion of week 1, 5 and 9; predose, week 2, 5, and 9, as well as at 48 and 96 hours of week 5, showed no clear dose proportionality in exposure between the 10 and 15 mg/kg dose groups. 

Assessment, Analysis, and Discussion {#onco12156-sec-6301}
====================================

CompletionStudy completedPharmacokinetics/PharmacodynamicsCorrelative endpoints metInvestigator\'s AssessmentCorrelative endpoints met but not powered to assess activity

 {#onco12156-sec-0010}

Trebananib is a first‐in‐class anti‐angiogenic agent that sequesters Ang‐1 and Ang‐2, preventing their interaction with the Tie‐2 receptor \[[1](#onco12156-bib-0001){ref-type="ref"}\], \[[2](#onco12156-bib-0002){ref-type="ref"}\]. Elevated serum Ang‐2 levels have been associated with a poor prognosis in hepatocellular carcinoma (HCC) \[[3](#onco12156-bib-0003){ref-type="ref"}\]. Furthermore, leveraging an anti‐angiogenic mechanism that is distinct from the classic anti‐vascular endothelial growth factor inhibition (VEGF), trebananib might be expected to provide a synergistic anti‐angiogenic effect when combined with anti‐VEGF therapies. The combination of trebananib plus sorafenib has been previously studied in renal cell carcinoma, where it showed a similar toxicity profile to that of sorafenib as single agent \[[4](#onco12156-bib-0004){ref-type="ref"}\]. While sorafenib remains the sole standard treatment of advanced HCC \[[5](#onco12156-bib-0005){ref-type="ref"}\], its efficacy is marginal, and better therapies are needed. We therefore evaluated the safety and efficacy of the combination of trebananib plus sorafenib in HCC.

Since the advent of sorafenib as a standard treatment of patients with advanced HCC \[[5](#onco12156-bib-0005){ref-type="ref"}\], improved anti‐angiogenic agents remain an attractive approach for the treatment of advanced HCC. Efforts to identify new agents have, however, been rather disappointing, with no evidence so far of improved overall survival beyond the 10.7 months that sorafenib has previously demonstrated \[[5](#onco12156-bib-0005){ref-type="ref"}\]. Herein, we studied the novel approach of targeting a non‐VEGF‐associated biological axis in angiogenesis, adding trebananib, which sequesters Ang‐1 and Ang‐2, preventing their interaction with the Tie‐2 receptor, to sorafenib treatment on a continuous schedule \[[1](#onco12156-bib-0001){ref-type="ref"}\]. This did not show an improvement in progression‐free survival (PFS) rate at 4 months, compared with the estimate of sorafenib in the historical registration study control, with similar demographics when compared with the present study (Table [1](#onco12156-tbl-0001){ref-type="table"}). This is, albeit a favorable median PFS of 7.9 for the 10 mg/kg arm, a reminder of the difficulty of interpreting these endpoints vis‐à‐vis the complexity of HCC and the accompanying cirrhosis. This, add to the length of time on therapy or of observation that may be needed before one may be able to discern any improved efficacy outcome.

The median duration of trebananib therapy given in the 10 mg/kg trebananib cohort was 5.5 months, with a range of 0.3--24.7 months, a median dose of 10.2 mg/kg, and a relative dose intensity of 99%. These figures were similar for the 15 mg/kg trebananib cohort. The median duration of trebananib therapy was 3.5 months (range 1 day to 21 months), with a median dose and relative dose intensity of 15.2 mg/kg and 99%, respectively.

The median duration of sorafenib therapy was 3.7 months (range 0.3--28 months), and the median dose was 744 mg daily with relative intensity of 87% for the 10 mg/kg trebananib cohort. These figures were similar for the 15 mg/kg trebananib cohort: the median duration of therapy was 3.7 months (range 0.13--21 months), with a median daily dose and relative intensity of 781 mg and 95%, respectively.

The outcome of this study may be explained in different ways. An alleged ceiling of benefit from anti‐angiogenic therapy may exist \[[6](#onco12156-bib-0006){ref-type="ref"}\]. In order to improve on existing approaches, combination studies that inhibit alternative targets or pathways will be required. The investigation of multiple novel approaches is underway \[[7](#onco12156-bib-0007){ref-type="ref"}\], including immunotherapeutic therapies \[[8](#onco12156-bib-0008){ref-type="ref"}\].

The combination of trebananib plus sorafenib seems relatively well tolerated. However, within the realm of this small, uncontrolled, sequentially enrolled study, the relatively higher than anticipated worsening of liver function is a concern and may add some pretext to the relatively poor outcome of the 15 mg/kg cohort compared with the 10 mg/kg cohort, raising the question of whether a higher dose would be necessary to achieve the potential synergy between trebananib and sorafenib. In support of this statement, the renal carcinoma study evaluated the combination of trebananib and sorafenib at 10 mg/kg and 3 mg/kg trebananib dose levels \[[4](#onco12156-bib-0004){ref-type="ref"}\]. The adverse event profiles of the studies have lot of similarities but differ in the degree of liver toxicity, which is reported at a higher rate in the present study, even at the 10 mg/kg dose. This is another reminder of the dual nature of HCC and the accompanying cirrhosis that may well render subjects more prone to certain toxicities that are not necessarily of concern otherwise. Liver failure was the cause of death in one patient in the HCC study and in none of the four adverse events‐related deaths on the renal study \[[4](#onco12156-bib-0004){ref-type="ref"}\].

The biomarker analyses showed several patterns that are exploratory in nature and would require further validation and confirmation. The most intriguing finding is the lower baseline Ang‐2 at study entry, suggesting an association with improved OS to 22 months. High Ang‐2 levels' association with poor outcome in HCC for patients treated with sorafenib or placebo has already been reported \[[9](#onco12156-bib-0009){ref-type="ref"}\]. The association between Ang‐2 and survival was previously observed (*p* \< .006) in a phase II trial of trebananib in combination with sunitinib in renal cancer patients \[[4](#onco12156-bib-0004){ref-type="ref"}\]. The higher Ang‐2 levels may indicate greater tumor angiogenic activity or metastatic potential \[[10](#onco12156-bib-0010){ref-type="ref"}\].

A relatively improved estimate of 17 months median OS of the 10 mg/kg compared with 11 months of the 15 mg/kg trebananib cohort, which is commensurate with the sorafenib single agent historical control of 10.7 months \[[5](#onco12156-bib-0005){ref-type="ref"}\], is noted. These values, however, have to be interpreted with caution given the limited sample size and the fact that these were sequentially accrued cohorts. We do not believe that the biology of trebananib could explain a lower dose improved efficacy or synergy with sorafenib. This may likely be an artifact of the Kaplan‐Meier curve estimation and censoring. The similar 4‐month PFS in the two arms of the study, plus the same duration and dose intensity, argue against any enhanced drug exposure advantage and thus against a treatment effect resulting in improved survival, except a delayed one that is not discernible except beyond 4 months, albeit with lack of any biologic argument to support it. An imbalance that is not accounted for may have influenced the point estimate of OS, which in both arms exceeds the single agent sorafenib estimate of 10.7 months.

In conclusion, the combination of sorafenib and trebananib did not demonstrate improved control of tumor growth at 4 months, the primary endpoint of this trial. Any further studies of this combination or similar in HCC should be studied within the context of low baseline Ang‐2 and possibly other markers reported herein.

Figures and Tables {#onco12156-sec-1512}
==================

###### Demographics (*n* = 60)

![](onco12156-tbl-0004){#nlm-graphic-11}

Abbreviations: ECOG, Eastern Cooperative Oncology Group; NASH, nonalcoholic steatohepatitis.
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[^1]: Abbreviations: NASH, nonalcoholic steatohepatitis.

[^2]: Abbreviations: NASH, nonalcoholic steatohepatitis.

[^3]: Grade 3 or greater treatment‐emergent adverse events that occurred in at least 10% of patients in either or both cohorts.

[^4]: \*NC/NA, no change from baseline/no adverse event.
